Fed. Circ. Amgen-Sandoz Ruling Extends Biologics Exclusivity
The Federal Circuit on Tuesday partly reversed Sandoz Inc.'s victory over Amgen Inc. in a major battle over requirements of the Affordable Care Act's biosimilars pathway, interpreting an advance-notice provision in...To view the full article, register now.
Already a subscriber? Click here to view full article